Senti Bio's Upcoming Investor Conferences
This fall, Senti Biosciences, Inc. (NASDAQ: SNTI) is gearing up to connect with investors as it highlights its innovative breakthroughs in biotechnology. Known for its cutting-edge Gene Circuit platform, Senti Bio is focused on developing next-generation cell and gene therapies. One of its key projects, SENTI-202, is currently undergoing Phase 1 clinical trials and is designed as a Logic Gated off-the-shelf CAR-NK investigational cell therapy.
Conference Participation Details
The company has confirmed its involvement in two major investor conferences:
H.C. Wainwright’s 26th Annual Global Investment Conference
This event will include presentations and one-on-one meetings, offering a fantastic opportunity for investors to gain insights into Senti Bio's developments. The recorded presentation will be available starting September 9, 2024, at 7:00 a.m. ET.
Chardan's 8th Annual Genetic Medicines Conference
This conference will feature a fireside chat format along with opportunities for one-on-one meetings. The live webcast for this event is set to begin on September 30, 2024, at 5:00 p.m. ET.
Archived Presentations
For those who cannot attend the live events, Senti Bio will offer archived replays accessible through the Events & Presentations section of their website for about 90 days following the events. Interested individuals can also contact the company via email to arrange one-on-one meetings.
Exploring SENTI-202
SENTI-202 represents a promising strategy for addressing hematologic malignancies. It is specifically designed to target cells expressing CD33 and FLT3, particularly in conditions such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), while ensuring the integrity of healthy bone marrow cells. This innovative therapy includes three essential components: an activating CAR that targets both CD33 and FLT3, a protective NOT GATE that allows healthy cells to remain unharmed, and a calibrated-release IL-15 technology that boosts the therapy's efficacy and durability.
Currently, Senti Bio is enrolling adult patients with recurrent or refractory hematologic malignancies to participate in the ongoing Phase 1 clinical trial for SENTI-202. Initial results from the trial are expected by the end of 2024, potentially paving the way for a groundbreaking allogeneic treatment option for patients with AML and MDS.
About Senti Bio's Broader Mission
Senti Bio is committed to developing advanced therapies using its proprietary synthetic biology platform, Gene Circuits. This platform aims to create treatments that selectively eliminate cancer cells while sparing healthy ones. The company is actively working to advance its wholly-owned pipeline, focusing on off-the-shelf CAR-NK cells integrated with these Gene Circuits to address challenging oncological conditions.
Moreover, Senti Bio has made significant progress in demonstrating the versatility of its Gene Circuits technology beyond oncology through partnerships with respected industry leaders. These collaborations aim to expand the range of therapeutic applications, enhancing treatment effectiveness across various disease areas.
Frequently Asked Questions
1. What is SENTI-202?
SENTI-202 is a CAR-NK cell therapy that targets CD33 and FLT3, which are expressed in malignancies like AML and MDS, while focusing on preserving healthy cells.
2. When will the results of the SENTI-202 clinical trial be available?
Senti Bio anticipates releasing the initial clinical trial results for SENTI-202 by the end of 2024.
3. How can investors access the presentations from the conferences?
The presentations will be made available on Senti Bio's website for approximately 90 days following the events.
4. What is the significance of the upcoming investor conferences?
These conferences provide Senti Bio with a platform to share their advancements and connect with potential investors and stakeholders.
5. How does Senti Bio leverage its Gene Circuit technology?
Senti Bio employs its Gene Circuit platform to create therapies that enhance specificity, control, and efficacy in targeting cancer cells.
